Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Si-Yang Liu

Showing results (111-120 of 141) with videos related to

Pageof 15
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2016
The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLCSi-Yang Liu, Lan-Ying Gou, An-Na Li, et al.
Clinical and Translational Medicine|June 9, 2020
Concomitant genetic alterations having greater impact on the clinical benefit of EGFR-TKIs in EGFR-mutant advanced NSCLC than BIM deletion polymorphismSi-Yang Liu, Jia-Ying Zhou, Wen-Feng Li, et al.
Clinical and Translational Medicine|April 22, 2022
Poor prognosis of intra-tumoural TRBV6-6 variants in EGFR-mutant NSCLC: Results from the ADJUVANT-CTONG1104 trialCunte Chen, Siyang Maggie Liu, Yedan Chen, et al.
Angewandte Chemie (International Ed. in English)|February 20, 2018
Electrochemical Exfoliation of Pillared-Layer Metal-Organic Framework to Boost the Oxygen Evolution ReactionJin Huang, Yun Li, Rui-Kang Huang, et al.
JCO Clinical Cancer Informatics|November 20, 2024
Waiting to Exhale: The Feasibility and Appropriateness of Home Blood Oxygen Monitoring in Oncology Patients Post-Hospital DischargeSi-Yang Liu, Sahil D Doshi, AnnMarie Mazzella Ebstein, et al.
Ebiomedicine|September 14, 2020
Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinomaHao Sun, Si-Yang Liu, Jia-Ying Zhou, et al.
Lung Cancer (Amsterdam, Netherlands)|November 16, 2018
Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancerSi-Yang Liu, Zhong-Yi Dong, Si-Pei Wu, et al.
The Journal of Allergy and Clinical Immunology|October 16, 2025
Radical-induced lipid oxidation produces a torrent of leukotriene-like agonists in severe asthmaSi-Yang Liu, Mikhail Linetsky, Abby Hite, et al.
Oncotarget|June 5, 2016
The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancerLan-Ying Gou, An-Na Li, Jin-Ji Yang, et al.
Experimental Hematology & Oncology|November 11, 2021
MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitorsLun-Xi Peng, Guang-Ling Jie, An-Na Li, et al.
Pageof 15

Showing results (111-120 of 141) with videos related to

Sort By:
Pageof 15
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2016
The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLCSi-Yang Liu, Lan-Ying Gou, An-Na Li, et al.
Clinical and Translational Medicine|June 9, 2020
Concomitant genetic alterations having greater impact on the clinical benefit of EGFR-TKIs in EGFR-mutant advanced NSCLC than BIM deletion polymorphismSi-Yang Liu, Jia-Ying Zhou, Wen-Feng Li, et al.
Clinical and Translational Medicine|April 22, 2022
Poor prognosis of intra-tumoural TRBV6-6 variants in EGFR-mutant NSCLC: Results from the ADJUVANT-CTONG1104 trialCunte Chen, Siyang Maggie Liu, Yedan Chen, et al.
Angewandte Chemie (International Ed. in English)|February 20, 2018
Electrochemical Exfoliation of Pillared-Layer Metal-Organic Framework to Boost the Oxygen Evolution ReactionJin Huang, Yun Li, Rui-Kang Huang, et al.
JCO Clinical Cancer Informatics|November 20, 2024
Waiting to Exhale: The Feasibility and Appropriateness of Home Blood Oxygen Monitoring in Oncology Patients Post-Hospital DischargeSi-Yang Liu, Sahil D Doshi, AnnMarie Mazzella Ebstein, et al.
Ebiomedicine|September 14, 2020
Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinomaHao Sun, Si-Yang Liu, Jia-Ying Zhou, et al.
Lung Cancer (Amsterdam, Netherlands)|November 16, 2018
Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancerSi-Yang Liu, Zhong-Yi Dong, Si-Pei Wu, et al.
The Journal of Allergy and Clinical Immunology|October 16, 2025
Radical-induced lipid oxidation produces a torrent of leukotriene-like agonists in severe asthmaSi-Yang Liu, Mikhail Linetsky, Abby Hite, et al.
Oncotarget|June 5, 2016
The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancerLan-Ying Gou, An-Na Li, Jin-Ji Yang, et al.
Experimental Hematology & Oncology|November 11, 2021
MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitorsLun-Xi Peng, Guang-Ling Jie, An-Na Li, et al.
Pageof 15